Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) insider Mitchell E. Levinson bought 4,261 shares of Pulse Biosciences stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $5.87 per share, for a total transaction of $25,012.07. Following the purchase, the insider now owns 73,027 shares of the company’s stock, valued at $428,668.49. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Pulse Biosciences Trading Down 1.9 %
PLSE opened at $6.12 on Friday. Pulse Biosciences, Inc. has a 12-month low of $1.65 and a 12-month high of $9.69. The business’s fifty day simple moving average is $4.51 and its 200-day simple moving average is $5.99. The company has a market capitalization of $336.54 million, a price-to-earnings ratio of -6.65 and a beta of 1.25.
Hedge Funds Weigh In On Pulse Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. grew its position in shares of Pulse Biosciences by 4.7% during the 2nd quarter. Osaic Holdings Inc. now owns 58,982 shares of the company’s stock worth $424,000 after buying an additional 2,672 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Pulse Biosciences by 2.1% during the 1st quarter. Geode Capital Management LLC now owns 142,490 shares of the company’s stock worth $479,000 after buying an additional 2,933 shares in the last quarter. BNP Paribas Arbitrage SNC grew its position in shares of Pulse Biosciences by 713.8% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 4,199 shares of the company’s stock worth $30,000 after buying an additional 3,683 shares in the last quarter. Bank of America Corp DE grew its position in shares of Pulse Biosciences by 0.5% during the 1st quarter. Bank of America Corp DE now owns 772,734 shares of the company’s stock worth $2,596,000 after buying an additional 3,994 shares in the last quarter. Finally, Citigroup Inc. bought a new position in shares of Pulse Biosciences during the 2nd quarter worth $35,000. Institutional investors own 6.62% of the company’s stock.
Analyst Ratings Changes
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
- Five stocks we like better than Pulse Biosciences
- Roth IRA Calculator: Calculate Your Potential Returns
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 11/13 – 11/17
- Pros And Cons Of Monthly Dividend Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.